Veracyte Inc (NASDAQ:VCYT) CFO Keith Kennedy sold 1,243 shares of the business’s stock in a transaction that occurred on Tuesday, October 22nd. The shares were sold at an average price of $28.00, for a total value of $34,804.00. Following the completion of the sale, the chief financial officer now owns 111,286 shares of the company’s stock, valued at $3,116,008. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Shares of VCYT stock opened at $20.78 on Friday. The stock has a 50 day simple moving average of $24.82 and a 200 day simple moving average of $25.64. Veracyte Inc has a 1 year low of $9.20 and a 1 year high of $31.18.
Veracyte (NASDAQ:VCYT) last issued its quarterly earnings results on Tuesday, October 22nd. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.05. Veracyte had a negative return on equity of 5.33% and a negative net margin of 7.08%. The business had revenue of $30.97 million during the quarter, compared to analysts’ expectations of $30.41 million. As a group, analysts predict that Veracyte Inc will post -0.23 earnings per share for the current year.
VCYT has been the subject of several recent research reports. Needham & Company LLC set a $34.00 price target on Veracyte and gave the company a “buy” rating in a research note on Wednesday, July 31st. ValuEngine cut Veracyte from a “hold” rating to a “sell” rating in a research note on Thursday. Zacks Investment Research upgraded Veracyte from a “hold” rating to a “buy” rating and set a $29.00 price target for the company in a research note on Saturday, October 19th. BidaskClub upgraded Veracyte from a “sell” rating to a “hold” rating in a research note on Friday, October 11th. Finally, TheStreet upgraded Veracyte from a “d” rating to a “c-” rating in a research note on Thursday, August 1st. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. Veracyte presently has a consensus rating of “Buy” and a consensus target price of $25.46.
Veracyte, Inc operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas solutions for a complex landscape in thyroid nodule diagnosis to physicians; Percepta Bronchial Genomic Classifier solution for use in lung cancer diagnosis; and Envisia Genomic Classifier solution for the diagnosis of idiopathic pulmonary fibrosis.
Recommended Story: What is the Rule of 72?
Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.